Betaseron
(Interferon beta-1b)Phase 3Small molecule
BayerInterferon beta-1b is used to treat multiple sclerosis, a disease where the immune system attacks nerve fibers in the brain and spinal cord, causing problems with movement and other functions. It helps reduce the frequency and severity of relapses in relapsing-remitting MS.[1] Betaseron is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Betaseron is one of 200 small molecule programs targeting Middle East respiratory syndrome. It is currently in Phase 3.
9
Indications
48
Total Trials
0
Active Trials
199
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Betaseron
BayerPhase 3
Biaxin
AbbViePreclinical
Aimovig
AmgenPreclinical
Statin
Bristol-Myers SquibbPreclinical
Statins
SanofiPreclinical
Orap
TevaPreclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Biological Data
UUniversity Hospital, Bordeaux
Preclinical
Aprotinin
BayerPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Sclerosis16 trials
Show 13 more trials
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
Completed·—··NCT00490906·60 enrolled
COVID-194 trials
Relapsing-Remitting Multiple Sclerosis4 trials
Treatment2 trials
14 more indications
Observational Study1 trial
Patient Satisfaction1 trial
Quality of Life1 trial
Prospective1 trial
Satisfaction1 trial
Combination Therapy1 trial
RRMS1 trial
Safety and Efficacy1 trial
Cytomegalovirus (CMV)1 trial
Unspecified8 trials
Regulatory
FDA Approval Timeline[4]
Jul 23, 1993
BETASERON
BLA BLA103471
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Interferon beta-1b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]